Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of SNG1005 versus single-agent chemotherapy in HER2-negative breast cancer with brain metastases after prior brain radiotherapy
ChiCTR1900027143Phase 3Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2019
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of paclitaxel trevatide in breast cancer and brain metastases (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: overall survival. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
paclitaxel trevatide
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on ChiCTR1900027143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027143.